Company Analysis Protalix BioTherapeutics, Inc.
1. Summary
Advantages
- The stock's return over the last year (19.77%) is higher than the sector average (3.63%).
- Current debt level 7.53% is below 100% and has decreased over 5 years from 94.8%.
- The company's current efficiency (ROE=7.64%) is higher than the sector average (ROE=-74.13%)
Disadvantages
- Price (2.06 $) is higher than fair price (0.58 $)
- Dividends (0%) are below the sector average (1.35%).
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Protalix BioTherapeutics, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -1.4% | -0.5% | -0.8% |
| 90 days | 17.7% | 6.7% | 1.8% |
| 1 year | 19.8% | 3.6% | 14% |
PLX vs Sector: Protalix BioTherapeutics, Inc. has outperformed the "Healthcare" sector by 16.14% over the past year.
PLX vs Market: Protalix BioTherapeutics, Inc. has outperformed the market by 5.82% over the past year.
Stable price: PLX is not significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: PLX with weekly volatility of 0.38% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Above fair price: The current price (2.06 $) is higher than the fair price (0.58 $).
Price is higher than fair: The current price (2.06 $) is 71.8% higher than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (52.25) is lower than that of the sector as a whole (142.07).
P/E vs Market: The company's P/E (52.25) is lower than that of the market as a whole (73.05).
5.2.1 P/E Similar companies
5.3. P/BV
P/BV vs Sector: The company's P/BV (3.55) is lower than that of the sector as a whole (18.06).
P/BV vs Market: The company's P/BV (3.55) is lower than that of the market as a whole (20.58).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (2.87) is lower than that of the sector as a whole (14.68).
P/S vs Market: The company's P/S indicator (2.87) is lower than that of the market as a whole (30.65).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (21.31) is lower than that of the sector as a whole (61.55).
EV/Ebitda vs Market: The company's EV/Ebitda (21.31) is lower than that of the market as a whole (36.29).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -21.69% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-21.69%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-72.41%).
6.4. ROE
ROE vs Sector: The company's ROE (7.64%) is higher than that of the sector as a whole (-74.13%).
ROE vs Market: The company's ROE (7.64%) is lower than that of the market as a whole (51.19%).
6.6. ROA
ROA vs Sector: The company's ROA (3.71%) is lower than that of the sector as a whole (6.62%).
ROA vs Market: The company's ROA (3.71%) is lower than that of the market as a whole (11.29%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (21.38%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (45.07%).
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.35%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Based on sources: porti.ru
